Navigation Links
Leviticus Cardio Ltd. Completes a Successful Animal Trial for its Wireless Energy System for VADs
Date:5/2/2013

TEL AVIV, Israel, May 2, 2013 /PRNewswire/ --

Leviticus Cardio, a portfolio company of the Mofet Venture Accelerator, owned by the Trendlines Group, recently performed a successful animal surgical trial using its wireless coplanar energy transfer system (CET) for ventricular assist devices (VAD). The surgery was performed at Assaf Harofeh Hospital and produced a 75% full system efficiency rate as compared with 78% efficiency in vitro.

The animal trials were done using the Leviticus CET system and Jarvik Heart VAD. The CET system performed the energy transfer to the animal body and controlled the VAD pump operation.

In vitro lab tests were conducted using several commercial VAD systems of Thoratec, Heartware, Jarvik Heart and Cleveland Heart . In all these tests, the Leviticus CET system was used to transfer the energy and to control the VAD pumping operation using the Leviticus advanced controller.

Leviticus Cardio was selected to present the results of these in vitro and in vivo tests as part of the scientific program in ISHLT 2013 convention held at Montreal.  

VADs are used to extend the lives of thousands of patients suffering from chronic heart failure or waiting for a heart transplant. Today, VAD patients are connected with wires to an external power supply - risking dangerous infections, repeated hospitalizations and severely limiting mobility. Leviticus Cardio's wireless CET system powers the VAD without wires, thereby avoiding the complications associated with today's technologies. In addition, the Leviticus Cardio's system can easily be removed for limited periods of time to give patients complete freedom of movement without any external device attached.

Michael Zilbershlag, Leviticus co-founder and CEO, stated, "This successful trial is a significant milestone in validating our technology and advancing towards commercialization. We are especially fortunate to be working with Prof. Stephan Schueler , M.D., a leading cardiothoracic surgeon in Europe and with the support from VAD manufacturer Jarvik Heart for the procedures."

Prof. Schueler remarked: "This new device allows us to apply the VAD technology to a wider group of patients outside of the transplant patients' group. For them, to have all the advantages of a wireless technology will have a huge impact on their morbidity and even mortality, and quite obviously on their quality of life."


Media relations:   Efrat Kaduri , Ofir Shpigel Media and Public Relations, +972-4-9535030


'/>"/>
SOURCE Leviticus Cardio Ltd
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Le cardio pourrait être la clé pour soigner le cancer
2. Emory Cardiologists Arshed Quyyumi And Javed Butler Join Stemedica Cardiology Division Scientific Advisory Board
3. ChanTest Introduces the CardioChannelGram™ and SaVety Assessment
4. Cardiovascular Drug Delivery - Technologies, Markets and Companies - 2013 Report
5. Douglas Harrington, MD Addresses Select Group Of Physicians Regarding Latest Advances In Cardiovascular Risk Assessment
6. CardioWise™ Welcomes Geoffrey Dalbow as Chief Technology Officer
7. Infinata’s BioPharm Insight Gears Up for the 2013 American College of Cardiology Meeting with the Release of its Cardiovascular Diseases Report
8. Stephen Epstein, MD To Head Scientific & Medical Advisory Board For Stemedica’s Cardiology Division
9. Interventional Cardiology Devices Market is Expected to Reach USD 25.2 Billion Globally in 2018: Transparency Market Research
10. Cardiometabolic Health Congress Expert Faculty Evaluate the Clinical Implications of Newly FDA-Approved Treatment for Homozygous Familial Hypercholesterolemia
11. Cardium Announces Patent Award For Rights To Cardiovascular Gene Therapy For The Treatment Of Heart Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, a leader in ... Trials Patient Recruitment and Retention Tips.” Partnering with experienced clinical research professionals, Mosio ... practical tips, tools, and strategies for clinical researchers. , “The landscape of how ...
(Date:6/23/2016)... June 23, 2016   Boston Biomedical , ... compounds designed to target cancer stemness pathways, announced ... granted Orphan Drug Designation from the U.S. Food ... gastric cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin ... to inhibit cancer stemness pathways by targeting STAT3, ...
(Date:6/23/2016)... , June 23, 2016 A person commits a ... crime scene to track the criminal down. An ... Food and Drug Administration (FDA) uses DNA evidence to track ... Sound far-fetched? It,s not. The FDA has increasingly ... support investigations of foodborne illnesses. Put as simply as possible, ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... YM (Yeast and Mold) microbial test has received AOAC Research Institute approval 061601. ... microbial tests introduced last year,” stated Bob Salter, Vice President of Regulatory and ...
Breaking Biology Technology:
(Date:5/12/2016)... WearablesResearch.com , a brand of Troubadour Research & ... Q1 wave of its quarterly wearables survey. A particular ... a program where they would receive discounts for sharing ... "We were surprised to see that so many ... CEO of Troubadour Research, "primarily because there are segments ...
(Date:4/28/2016)... 2016 First quarter 2016:   ... with the first quarter of 2015 The gross margin ... (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) , ... unchanged, SEK 7,000-8,500 M. The operating margin for 2016 ...
(Date:4/15/2016)... April 15, 2016  A new partnership announced ... accurate underwriting decisions in a fraction of the ... priced and high-value life insurance policies to consumers ... With Force Diagnostics, rapid testing (A1C, Cotinine ... readings (blood pressure, weight, pulse, BMI, and activity ...
Breaking Biology News(10 mins):